QSP programs

Liver MicroPhysiology Systems (MPS) for Experimentally Modelling Disease and Safety

 

 

We have developed a platform that includes a human, 4 cell, microfluidic, 3D liver microphysiological system to investigate human toxicology and liver diseases applied to several studies including: a Resource for Organotypic Models for Predictive Toxicology, and the Use of Encapsulated Human Hepatocytes to Retrofit ToxCast/Tox21 Assays For in situ Metabolic Activation of Test Agents (both funded by the EPA); and the development and evaluation of the HepaPlate iPS: a high-throughput organ-on-a-chip iPS hepatotoxicity screening platform (an NCATS funded SBIR in collaboration with https://mimetas.com/).

 

Experimental models of liver diseases include non-alcoholic fatty liver disease, diabetic liver disease, the liver as a metastatic site for metastatic breast cancer and metastatic melanoma, and hepatocarcinoma.

 

In addition to our Liver MPS efforts, we have designed a database to aggregate and manage all types of MPS data, integrate MPS data with human and animal exposure data, and to enable the evaluation of MPS results with reference and clinical data.  The MPS-Db provides user access over the internet to access and retrieve relevant data from other internet databases, and access MPS data in a secure manner.  (Gough et al, Applied In Vitro Tox., 2:103, 2016).  mps.csb.pitt.edu


Lee-Montiel, F.T., et al. ExpBiol Med (Maywood), 2017